Genes associated with antibody-dependent cell activation are overexpressed in renal biopsies from patients with antibody-mediated rejection

Transplant Immunology

Volumn 32, Issue 1, 2015, Pages 9-17

  Suviolahti, Elina ^a   Ge, Shili ^a   Nast, Cynthia C ^a   Mirocha, James ^a   Karasyov, Artur ^a   White, Molly ^a   Jordan, Stanley C ^a   Toyoda, Mieko ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Anti HLA antibody; Antibody dependent cellular cytotoxicity; Antibody mediated allograft rejection; Gene expression; Kidney biopsy; Natural killer cell

Indexed keywords

ALEMTUZUMAB; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; CYCLOSPORIN; DACLIZUMAB; GAMMA INTERFERON; HLA ANTIBODY; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MESSENGER RNA; MYCOPHENOLIC ACID; NUCLEAR RECEPTOR NR4A3; PREDNISONE; TACROLIMUS; ALLOANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; ARTICLE; CCL3 GENE; CCL4 GENE; CCL4L1 GENE; CCL4L2 GENE; CD160 GENE; CONTROLLED STUDY; FEMALE; GENE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IFNG GENE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; NR4A3 GENE; XCL1 GENE; XCL2 GENE; ALLOGRAFT; BIOPSY; CLINICAL TRIAL; GENE EXPRESSION REGULATION; GRAFT REJECTION; IMMUNOLOGY; KIDNEY; MALE; PATHOLOGY;

ALLOGRAFTS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BIOPSY; FEMALE; GENE EXPRESSION REGULATION; GRAFT REJECTION; HUMANS; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; MALE; RNA, MESSENGER;

EID: 84920403819     PISSN: 09663274     EISSN: 18785492     Source Type: Journal    
DOI: 10.1016/j.trim.2014.11.215     Document Type: Article

References (39)

1. Akalin E., Bromberg J.S. Intravenous immunoglobulin induction treatment in flow cytometry cross-match-positive kidney transplant recipients. Hum Immunol 2005, 66(4):359-363.
2. Deng M.C., Eisen H.J., Mehra M.R., Billingham M., Marboe C.C., Berry G., et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006, 6(1):150-160.
3. Einecke G., Sis B., Reeve J., Mengel M., Campbell P.M., Hidalgo L.G., et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009, 9(11):2520-2531.
4. Haas M., Sis B., Racusen L.C., Solez K., Glotz D., Colvin R.B., et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014, 14(2):272-283.
5. Hidalgo L.G., Einecke G., Allanch K., Halloran P.F. The transcriptome of human cytotoxic T cells: similarities and disparities among allostimulated CD4(+) CTL, CD8(+) CTL and NK cells. Am J Transplant 2008, 8(3):627-636.
6. Hidalgo L.G., Sellares J., Sis B., Mengel M., Chang J., Halloran P.F. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant 2012, 12(5):1180-1191.
7. Hidalgo L.G., Sis B., Sellares J., Campbell P.M., Mengel M., Einecke G., et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010, 10(8):1812-1822.
8. Hirohashi T., Chase C.M., Della Pelle P., Sebastian D., Alessandrini A., Madsen J.C., et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012, 12(2):313-321.
9. Hirohashi T., Uehara S., Chase C.M., Della Pelle P., Madsen J.C., Russell P.S., et al. Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice. Am J Transplant 2010, 10(3):510-517.
10. Idriss H.T., Naismith J.H. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000, 50(3):184-195.
11. Jordan S.C., Reinsmoen N., et al. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol 2010, 25(10):2035-2045. [quiz 2045-2038].
12. Knorr M., Munzel T., Wenzel P. Interplay of NK cells and monocytes in vascular inflammation and myocardial infarction. Front Physiol 2014, 5:295.
13. Lai C.H., Cao K., Ong G., Naim M., Wang Q., Mirocha J., et al. Antibody testing strategies for deceased donor kidney transplantation after immunomodulatory therapy. Transplantation 2011, 92(1):48.
14. Le Bouteiller P., Tabiasco J., Polgar B., Kozma N., Giustiniani J., Siewiera J., et al. CD160: a unique activating NK cell receptor. Immunol Lett 2011, 138(2):93-96.
15. Lee C.Y., Lotfi-Emran S., Erdinc M., Murata K., Velidedeoglu E., Fox-Talbot K., et al. The involvement of FcR mechanisms in antibody-mediated rejection. Transplantation 2007, 84(10):1324-1334.
16. Lo D.J., Weaver T.A., Kleiner D.E., Mannon R.B., Jacobson L.M., Becker B.N., et al. Chemokines and their receptors in human renal allotransplantation. Transplantation 2011, 91(1):70-77.
17. Mengel M., Sis B., Haas M., Colvin R.B., Halloran P.F., Racusen L.C., et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012, 12(3):563-570.
18. Morris M.A., Ley K. Trafficking of natural killer cells. Curr Mol Med 2004, 4(4):431-438.
19. Patino-Lopez G., Hevezi P., Lee J., Willhite D., Verge G.M., Lechner S.M., et al. Human class-I restricted T cell associated molecule is highly expressed in the cerebellum and is a marker for activated NKT and CD8+ T lymphocytes. J Neuroimmunol 2006, 171(1-2):145-155.
20. Pober J.S., Gimbrone M.A., Lapierre L.A., Mendrick D.L., Fiers W., Rothlein R., et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol 1986, 137(6):1893-1896.
21. Racusen L.C., Haas M. Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol 2006, 1(3):415-420.
22. Reeve J., Einecke G., Mengel M., Sis B., Kayser N., Kaplan B., et al. Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplant 2009, 9(8):1802-1810.
23. Reinsmoen N.L., Lai C.H., Vo A., Cao K., Ong G., Naim M., et al. Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy. Transplantation 2008, 86(6):820-825.
24. Richards J.O., Karki S., Lazar G.A., Chen H., Dang W., Desjarlais J.R., et al. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008, 7(8):2517-2527.
25. Rodrigo E., Arias M. A practical approach to immune monitoring in kidney transplantation. Minerva Urol Nefrol 2007, 59(3):337-352.
26. Sellares J., Reeve J., Loupy A., Mengel M., Sis B., Skene A., et al. Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Am J Transplant 2013, 13(4):971-983.
27. Sis B., Campbell P.M., Mueller T., Hunter C., Cockfield S.M., Cruz J., et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007, 7(7):1743-1752.
28. Sis B., Jhangri G.S., Bunnag S., Allanach K., Kaplan B., Halloran P.F. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009, 9(10):2312-2323.
29. Sis B., Mengel M., Haas M., Colvin R.B., Halloran P.F., Racusen L.C., et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant 2010, 10(3):464-471.
30. Solez K., Colvin R.B., Racusen L.C., Sis B., Halloran P.F., Birk P.E., et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007, 7(3):518-526.
31. Stegall M.D., Chedid M.F., Cornell L.D., et al. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012, 8(11):670-678.
32. Stegall M.D., Diwan T., Raghavaiah S., Cornell L.D., Burns J., Dean P.G., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011, 11(11):2405-2413.
33. Toyoda M., Ge S., Pao A., Vo A., Deer N., Aguiluz A., et al. Cellular allo reactivity against paternal HLA antigens in normal multiparous females as detected by intracellular cytokine flow cytometry remains elevated over years despite diminution of anti-HLA antibody levels. Transpl Immunol 2010, 23(3):133-140.
34. Toyoda M., Ge S., Suviolahti E., Pichurin P., Shin B., Pao A., et al. IFNgamma production by NK cells from HLA-sensitized patients after in vitro exposure to allo-antigens. Transpl Immunol 2012, 26(2-3):107-112.
35. Toyoda M., Pao A., Vo A., Lukovsky M., Radha R., Sado T., et al. Intracellular IFNgamma production in CD3 negative cells exposed to allo-antigens is an indicator of prior sensitization. Transpl Immunol 2010, 22(3-4):121-127.
36. Truong L.D., Barrios R., Adrogue H.E., Gaber L.W., et al. Acute antibody-mediated rejection of renal transplant: pathogenetic and diagnostic considerations. Arch Pathol Lab Med 2007, 131(8):1200-1208.
37. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S., et al. Functions of natural killer cells. Nat Immunol 2008, 9(5):503-510.
38. Vo A.A., Lukovsky M., Toyoda M., Wang J., Reinsmoen N.L., Lai C.H., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008, 359(3):242-251.
39. Vo A.A., Toyoda M., Peng A., Bunnapradist S., Lukovsky M., Jordan S. Effect of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG. Am J Transplant 2006, 6(10):2384-2390.